PCK

0.00%

3.0¢ painchek ltd

I think you are right about the incorporation of what is best....

First 26 Last

Share
Profile

Follow
zidane123

584 Posts.

121

02/07/19

10:20

Post #: 39329719
Share

Originally posted by fattchoi ↑

PainChek® partners with the Melbourne Murdoch Children’s Research Institute (MCRI) for Infant App PainFaces Study

In this new study, which is expected to commence within days, the pain scores derived using the PainChek® Infant App will be compared to those obtained using observational children’s pain assessment tools by two independent assessors in approx. 100 infants undergoing painful procedures within the ED

Results and lessons from the research will support applications for regulatory approval of PainChek® Infant’s App with the Therapeutics Goods Administration (TGA), CE Mark, Europe, and the Food and Drug Administration (FDA) in the USA.

The first paragraph above says it is a STUDY. Not trial of the app.
The second paragraph says the they are comparing scores of the Infant App against the two independent assessors. It is like, see where they agree, and where they do not. So both parties are on trial here in a sense. And I think where they agree, they will adopt and use. While where they don't agree, maybe a bit more work to be done to prove up who is right and wrong.
Then the third paragraph says results and lessons from research will be used to apply for regulatory approvals.

Well, the more I read it, the more I think this is going to be a slam-dunk outcome. After all, since these assessors method is already in used, so where both the app and the assessors agree, then that part of the app will be approved. So really, what I am saying is this is merely a process to gain regulatory approval rather than a trial to see if it should gain regulatory approval.

If I am right, then it is only a matter of when rather than if the app will gain approval and be released to the market in general

Expand

I think you are right about the incorporation of what is best. It is an evolution of the current best practice methods with new technology.

PCK Price at posting: 22.0¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 44 more messages in this thread...

First 26 Last

Add PCK (ASX) to my watchlist

(20min delay)
Last 3.0¢		Change 0.000(0.00%)		Mkt cap ! $49.07M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	546666	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.1¢	129158	2

View Market Depth

No.	Vol.	Price($)
3	546666	0.030
5	9463448	0.029
1	98344	0.027
3	1580000	0.026
1	100000	0.010

Price($)	Vol.	No.
0.031	129158	2
0.033	379500	2
0.034	79638	2
0.035	125000	1
0.036	200000	1

Last trade - 16.33pm 27/09/2024 (20 minute delay)

PCK (ASX) Chart

Day chart unavailable

I think you are right about the incorporation of what is best....

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Zeta Resources seeks to resolve the Panoramic takeover story

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I think you are right about the incorporation of what is best....

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Zeta Resources seeks to resolve the Panoramic takeover story

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News